ADAM12 and esophageal cancer: In addition, the analysis of gene expression profiles of patients with esophageal cancer identified ADAM12 as a noninflammatory-related serum marker for IL-6-producing CAFs, and serum levels of ADAM12 predicted unfavorable responses to neoadjuvant chemoradiation.